MLchartDataset catalogue

anti-PD-1/IL-2 bispecific antibody fusion protein IBI363

Term · Oncology and biomedicine · MLC-T-ONC-010989

A bispecific antibody fusion protein composed of a monoclonal antibody targeting the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and fused to a mutated form of the endogenous cytokine interleukin-2 (IL-2), with potential immunostimulating and antineoplastic activities. Upon administration, anti-PD-1/IL-2 bispecific antibody fusion protein IBI363 targets and binds to PD-1 expressed on PD-1-expressing T cells, thereby inhibiting PD-1-mediated signaling. This may restore immune function through the activation of T cells and T-cell-mediated immune responses against tumor cells. IL-2 targets and binds to the IL-2 receptor IL2R and activates IL-2/IL-2R-mediated signaling, which further activates cytotoxic T-lymphocytes (CTLs) and natural killer (NK) cells, and induces expression of certain cytotoxic cytokines, such as interferon-gamma (IFNg) and transforming growth factor-beta (TGFb). This further enhances T-cell-mediated cytotoxic immune responses against tumor cells. By selectively activating PD-1 positive T cells by IL-2, but not PD-1 negative bystander or naïve T cells, the activity of tumor-specific T cells is specifically enhanced while IL-2-induced systemic toxicity is decreased. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.

Table 1. Record
IdentifierMLC-T-ONC-010989
FieldOncology and biomedicine
Synonymsfusion protein IBI363; PD-1/IL-2 bispecific molecule IBI363; anti-PD-1/IL-2 bispecific fusion protein IBI363
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-010989",
  "term": "anti-PD-1/IL-2 bispecific antibody fusion protein IBI363",
  "field": "Oncology and biomedicine",
  "definition": "A bispecific antibody fusion protein composed of a monoclonal antibody targeting the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and fused to a mutated form of the endogenous cytokine interleukin-2 (IL-2), with potential immunostimulating and antineoplastic activities. Upon administration, anti-PD-1/IL-2 bispecific antibody fusion protein IBI363 targets and binds to PD-1 expressed on PD-1-expressing T cells, thereby inhibiting PD-1-mediated signaling. This may restore immune function through the activation of T cells and T-cell-mediated immune responses against tumor cells. IL-2 targets and binds to the IL-2 receptor IL2R and activates IL-2/IL-2R-mediated signaling, which further activates cytotoxic T-lymphocytes (CTLs) and natural killer (NK) cells, and induces expression of certain cytotoxic cytokines, such as interferon-gamma (IFNg) and transforming growth factor-beta (TGFb). This further enhances T-cell-mediated cytotoxic immune responses against tumor cells. By selectively activating PD-1 positive T cells by IL-2, but not PD-1 negative bystander or naïve T cells, the activity of tumor-specific T cells is specifically enhanced while IL-2-induced systemic toxicity is decreased. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.",
  "synonyms": [
    "fusion protein IBI363",
    "PD-1/IL-2 bispecific molecule IBI363",
    "anti-PD-1/IL-2 bispecific fusion protein IBI363"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-pd-1-il-2-bispecific-antibody-fusion-protein-ibi363/"
}

Record 2,119 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.